Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Significant Drop in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 91,300 shares, a decrease of 13.6% from the January 31st total of 105,700 shares. Based on an average trading volume of 142,000 shares, the short-interest ratio is currently 0.6 days. Currently, 0.2% of the shares of the stock are short sold.

Xtant Medical Stock Down 5.0 %

Xtant Medical stock traded down $0.02 during mid-day trading on Monday, reaching $0.44. 31,955 shares of the company's stock traded hands, compared to its average volume of 94,226. Xtant Medical has a 12-month low of $0.33 and a 12-month high of $1.24. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.88 and a current ratio of 2.12. The firm's 50 day moving average price is $0.52. The stock has a market capitalization of $60.89 million, a P/E ratio of -3.37 and a beta of 0.35.

Institutional Trading of Xtant Medical

A hedge fund recently raised its stake in Xtant Medical stock. Renaissance Technologies LLC boosted its position in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 798,033 shares of the medical device company's stock after buying an additional 103,825 shares during the quarter. Renaissance Technologies LLC owned 0.57% of Xtant Medical worth $354,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 69.33% of the company's stock.

Remove Ads

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.